Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Amylyx Pharmaceuticals Inc and keeping the price target at $24.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Rami Katkhuda’s rating is based on the promising early safety and tolerability data from Amylyx Pharmaceuticals’ Phase I LUMINA study, which evaluates AMX0114 in ALS. The treatment has shown to be generally well-tolerated with no serious treatment-related adverse events, marking a positive step in its clinical development.
Furthermore, AMX0114’s specificity in inhibiting calpain-2, a target implicated in neurodegenerative diseases, without affecting other calpains, highlights its potential therapeutic advantage. The company’s strategic plans to advance to the second cohort and the anticipated biomarker data in 2026 further support the Buy rating, as these developments could significantly enhance the drug’s clinical profile and market potential.